Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Rznomics Inc. logo — Development of innovative treatments for cancer & intractabl...

Rznomics Inc.

Development of innovative treatments for cancer & intractable diseases through the RNA-based platform technology

Founded 2017 Korea South Korea South 11 employees Series C Total: $59.70B Biopharma, Biotechnology

General Information

Company Name Rznomics Inc.
Founded Year 2017
Location Korea South Korea South
Employees 11
Industries Biopharma, Biotechnology
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Rznomics Inc.. To contact Rznomics Inc., visit rznomics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Rznomics Inc. compare?

A PDF of Rznomics Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Rznomics Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Rznomics Inc.

Rznomics Inc. is a biopharmaceutical startup focused on developing innovative treatments for cancer and intractable diseases through its RNA-based platform technology called trans-splicing ribozyme. Established in 2017, Rznomics has gained recognition from bio-focused institutions and successfully raised a total of KRW 60.9 billion in funding, including a recent KRW 37.2 billion series C investment from Korea Development Bank, Partners Investment, IBK Capital, UTC 2019 BioVentureFund, QUAD Ventures, Shinhan Venture Investment, Aon, and SBI Investment Korea. In 2022 1H, Rznomics achieved a significant milestone with the approval of its RZ-001 IND submission for the HCC treatment by the MFDS, and the clinical trial for RZ-001 is underway. The company also boasts a robust pipeline including treatments for glioblastoma multiforme, Alzheimer’s disease, genetic ocular disease (retinitis pigmentosa), and circular RNA technology. Additionally, Rznomics is actively engaging in partnerships with global companies to explore opportunities for co-research, co-development, and licensing. Rznomics' dedication to developing safe and effective biopharmaceuticals in oncology, degenerative disease, and genetic disease, coupled with its strategic partnerships and substantial funding, positions the company as a promising player in the biopharma and biotechnology industries.

Business keywords: biopharmaceuticals, RNA-based platform technology, oncology, genetic disease, trans-splicing ribozyme, clinical trials, new drug development, gene therapy, Alzheimer's disease, global partnerships, TIPS program, innovation, research funding, tagging not forced

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series C KRW37.20B 8
Korea Development Bank Partners Investment IBK Capital
Korea Development Bank, Partners Investment +6
08 Jun 2022
Series B KRW10.50B 2
Partners Investment
Partners Investment, Synergy IB Investment
16 Apr 2021
Series A KRW12.00B -
30 Oct 2019

Rznomics Inc. Alternatives & Competitors

View All Alternatives
Rznomics Inc. vs
Arno Therapeutics Inc (ARNI)
Arno Therapeutics Inc (ARNI)

Arno Therapeutics Inc (ARNI) is a pharmaceuticals company based out of Parsippany, NJ, United States...

Post-IPO Equity
3 employees
Biopharma, Biotechnology
Rznomics Inc. vs
Ethris
Ethris Germany

Clinical stage biotech company focused on development of disruptive mRNA therapeutics for severe res...

Venture round
34 employees
Biopharma, Biotechnology
Rznomics Inc. vs
Selonterra, Inc.
Selonterra, Inc. United States

Therapy of neurodegenerative disorders by harnessing human genetics and gene regulatory networks.

Grant
3 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Rznomics Inc.

Development of innovative treatments for cancer & intractable diseases through the RNA-based platform technology
Rznomics Inc. was founded in 2017.
Rznomics Inc. is headquartered in Korea South.
Rznomics Inc. operates in Biopharma and Biotechnology. Its work centres on biopharmaceuticals, RNA-based platform technology, oncology and genetic disease.
Rznomics Inc. has approximately 11 employees.
Rznomics Inc. has completed 3 funding rounds, raising a total of $59.70B. The latest funding stage is Series C.
Top alternatives and competitors to Rznomics Inc. include Arno Therapeutics Inc (ARNI), Ethris, Selonterra, Inc., Sitka Biopharma, Yuanyin Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Rznomics Inc. and Arno Therapeutics Inc (ARNI) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Rznomics Inc., https://bouncewatch.com/company/rznomics-inc, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout